Celgene Corporation (CELG) Stake Maintained by Fairfield Bush & CO.
Fairfield Bush & CO. continued to hold its position in Celgene Corporation (NASDAQ:CELG) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 13,080 shares of the biopharmaceutical company’s stock at the end of the first quarter. Fairfield Bush & CO.’s holdings in Celgene Corporation were worth $1,628,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also bought and sold shares of CELG. Bank of New York Mellon Corp boosted its position in Celgene Corporation by 4.9% in the first quarter. Bank of New York Mellon Corp now owns 10,088,473 shares of the biopharmaceutical company’s stock worth $1,255,309,000 after buying an additional 472,067 shares during the last quarter. American Century Companies Inc. boosted its position in Celgene Corporation by 4.4% in the first quarter. American Century Companies Inc. now owns 6,563,791 shares of the biopharmaceutical company’s stock worth $816,733,000 after buying an additional 276,089 shares during the last quarter. Norges Bank acquired a new position in Celgene Corporation during the fourth quarter worth about $694,111,000. Pioneer Investment Management Inc. boosted its position in Celgene Corporation by 15.7% in the first quarter. Pioneer Investment Management Inc. now owns 5,231,139 shares of the biopharmaceutical company’s stock worth $650,911,000 after buying an additional 710,584 shares during the last quarter. Finally, Bank of Montreal Can boosted its position in Celgene Corporation by 149.8% in the first quarter. Bank of Montreal Can now owns 3,299,988 shares of the biopharmaceutical company’s stock worth $410,615,000 after buying an additional 1,979,061 shares during the last quarter. 78.34% of the stock is owned by hedge funds and other institutional investors.
Shares of Celgene Corporation (NASDAQ:CELG) traded up 0.05% during midday trading on Friday, reaching $127.65. The company had a trading volume of 4,270,548 shares. Celgene Corporation has a one year low of $96.93 and a one year high of $139.00. The company has a 50 day moving average price of $133.74 and a 200-day moving average price of $124.92. The firm has a market capitalization of $99.87 billion, a P/E ratio of 39.53 and a beta of 1.89.
Celgene Corporation (NASDAQ:CELG) last posted its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 EPS for the quarter, topping analysts’ consensus estimates of $1.61 by $0.21. The company had revenue of $3.27 billion for the quarter, compared to analysts’ expectations of $3.23 billion. Celgene Corporation had a net margin of 21.35% and a return on equity of 68.51%. Celgene Corporation’s revenue was up 18.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.44 EPS. On average, analysts anticipate that Celgene Corporation will post $7.32 EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This piece was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another publication, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2017/08/19/fairfield-bush-co-has-1628000-stake-in-celgene-corporation-celg-updated-updated-updated.html.
A number of research analysts have issued reports on CELG shares. BTIG Research cut Celgene Corporation from a “buy” rating to a “neutral” rating and boosted their target price for the company from $96.93 to $131.70 in a research note on Friday, June 30th. Leerink Swann restated an “outperform” rating and issued a $160.00 price target (up from $150.00) on shares of Celgene Corporation in a report on Friday, July 28th. Argus upgraded Celgene Corporation from a “hold” rating to a “buy” rating and boosted their price target for the company from $96.93 to $160.00 in a report on Monday, July 31st. Credit Suisse Group set a $148.00 price target on Celgene Corporation and gave the company a “buy” rating in a report on Thursday, July 6th. Finally, Cann restated a “buy” rating on shares of Celgene Corporation in a report on Wednesday, June 7th. One research analyst has rated the stock with a sell rating, six have issued a hold rating, twenty-two have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Celgene Corporation has an average rating of “Buy” and an average price target of $147.00.
In other Celgene Corporation news, Director Ernest Mario sold 18,506 shares of the business’s stock in a transaction on Thursday, August 10th. The shares were sold at an average price of $130.52, for a total transaction of $2,415,403.12. Following the sale, the director now owns 69,424 shares of the company’s stock, valued at approximately $9,061,220.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Rupert Vessey sold 4,785 shares of the business’s stock in a transaction on Thursday, June 15th. The shares were sold at an average price of $120.18, for a total transaction of $575,061.30. Following the sale, the insider now directly owns 4,004 shares in the company, valued at approximately $481,200.72. The disclosure for this sale can be found here. Insiders sold a total of 253,761 shares of company stock worth $33,792,445 in the last ninety days. 0.95% of the stock is currently owned by insiders.
Celgene Corporation Company Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Stock Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related stocks with our FREE daily email newsletter.